IMMX vs IMRX

Immix Biopharma, Inc. vs Immuneering Corporation — Valuation Comparison 2026

IMMX

Biotechnology
Immix Biopharma, Inc.
Quality
5.1
out of 10
Value Trap
30
LOW
Price
$8.84
Last close
Models
8/13
Active
VS

IMRX

Biotechnology
Immuneering Corporation
Quality
4.5
out of 10
Value Trap
26
LOW
Price
$5.06
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType IMMX Fair ValueIMMX Upside IMRX Fair ValueIMRX Upside
Bayesian DCF Intrinsic $2.98 -66.3% $1.74 -65.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.66 -67.2%
Dynamic NAV Asset-Based $1.23 -86.1% $2.65 -47.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for IMMX vs IMRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IMMX vs IMRX — Which Stock Is More Undervalued?

IMMX scores higher with a 5.1/10 quality rating vs IMRX's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Immix Biopharma, Inc. (IMMX) and Immuneering Corporation (IMRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IMMX currently trades at $8.84 with a QOC of 5.1/10, while IMRX trades at $5.06 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).